Coleman's 2001 narrative review synthesizes the pathophysiology, natural history, and treatment of metastatic bone disease, focusing on breast cancer, prostate cancer, and multiple myeloma. It asks how tumor-bone cell interactions drive skeletal complications and how bisphosphonates fit alongside radiotherapy and systemic anticancer treatment. The review establishes key clinical thresholds — particularly the one-third cortical destruction rule — and summarizes landmark bisphosphonate trial data.
Every cancer patient with a lytic long bone lesion needs an orthopedic eye on it before it fractures. Coleman puts the number in your hands: once cortical destruction exceeds one-third of the bone's diameter, fracture risk climbs to ~80%. A pathological fracture in a known metastatic patient is, in Coleman's words, "a reflection of inadequate clinical management" — not an inevitable outcome.
When you see that threshold crossed, the action is prophylactic fixation followed by radiotherapy. Do not do one without the other: fixation without radiation leaves the tumor growing at the implant edges, and radiation alone cannot restore structural integrity.
For spinal metastases causing back pain, distinguish mechanical instability (pain only relieved by lying still, unresponsive to radiation) from tumor-driven pain. Instability requires surgical stabilization. No amount of radiotherapy will fix it.
This review also explains why IV bisphosphonates are standard of care for hypercalcaemia of malignancy (70–90% normocalcaemia rate) and why neurological recovery from cord compression requires decompression within 24–48 hours. Two facts that belong on every oncology-adjacent call.
Coleman's 2001 narrative review synthesizes the pathophysiology, natural history, and treatment of metastatic bone disease, focusing on breast cancer, prostate cancer, and multiple myeloma. It asks how tumor-bone cell interactions drive skeletal complications and how bisphosphonates fit alongside radiotherapy and systemic anticancer treatment. The review establishes key clinical thresholds — particularly the one-third cortical destruction rule — and summarizes landmark bisphosphonate trial data.
Every cancer patient with a lytic long bone lesion needs an orthopedic eye on it before it fractures. Coleman puts the number in your hands: once cortical destruction exceeds one-third of the bone's diameter, fracture risk climbs to ~80%. A pathological fracture in a known metastatic patient is, in Coleman's words, "a reflection of inadequate clinical management" — not an inevitable outcome.
When you see that threshold crossed, the action is prophylactic fixation followed by radiotherapy. Do not do one without the other: fixation without radiation leaves the tumor growing at the implant edges, and radiation alone cannot restore structural integrity.
For spinal metastases causing back pain, distinguish mechanical instability (pain only relieved by lying still, unresponsive to radiation) from tumor-driven pain. Instability requires surgical stabilization. No amount of radiotherapy will fix it.
This review also explains why IV bisphosphonates are standard of care for hypercalcaemia of malignancy (70–90% normocalcaemia rate) and why neurological recovery from cord compression requires decompression within 24–48 hours. Two facts that belong on every oncology-adjacent call.